DBV Technologies (DBVT)

DBV Technologies (DBVT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $663M; returns 1 day +0.7%, 1 week +7.7%, 1 year -34.4%.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing epicutaneous immunotherapy (EPIT) products for patients with food allergies and other immunological diseases. The company's proprietary Viaskin® patch technology is designed to deliver biologically active compounds across intact skin without needles, aiming to re-educate the immune system.

Groups DBVT belongs to

• Shrinking Share Count
• Biotechnology
• Clinical Stage
• Clinical Stage Biotech
• Biopharmaceutical
• Immunotherapy
• Healthcare
• Life Sciences
• Rare Diseases

DBVT financial model: income statement, cash flow and balance sheet